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Approximately 1 out of every 2000 births in the United States is affected by
neural tube defects. The most well-known environmental cause of neural tube
malformation is folate deficiency in pregnant women. The underlying mechanism for this
relationship is unclear. The goal of this study was to determine if altered folate
metabolism during early development leads to changes in the expression of selected
genes. Xenopus laevis embryos were treated with different concentrations of
homocysteine (0.5 mM, 1 mM, 10 mM, 25 mM , 50 mM and 100 mM) and methotrexate
(1 µM, 10 µM, 50 µM, 100 µM and 200 µM) and their gross morphology, direction of
gut coiling and neural tube thickness were analyzed. At higher concentrations both
compounds caused morphological defects, including delayed development, kinked
bodies, reduced body size and lack of gut structure. The percent of guts coiling to the left
decreased from 93% to 5% as the homocysteine concentration increased from 0 mM to
10 mM. Meanwhile the guts coiling to the right increased from about 5% to 39%. The
percent of guts deformed or mis-coiled increased from 5% to 100%, with the
homocysteine concentration increasing from 0 mM to 50 mM. Methotrexate also affected
the morphology and direction of gut coiling in a concentration dependent manner. The
thickness of the dorsal side of the neural tube of the methotrexate treated embryos
decreased from about 6 mm to 3 mm as the concentration increased from 0 µM – 200
µM. The effect of homocysteine on the neural tube thickness was less clear. Gross
morphological effects and gut coiling suggest treatment of embryos with homocysteine
and methotrexate affect embryos in a similar manner consistent with folate deficiency. In
situ hybridization was performed on treated and untreated embryos to analyze changes in
expression patterns of Dkk-1, Pax-3, Xbra, Xtwist and Wnt-5A genes. Gene expression
patterns of Xbra and Xtwist were not affected by folate deficiency whereas Dkk-1 and
Pax-3 expression appear to be down regulated. Wnt-5A data were inconclusive. These
findings suggest that specific gene expression changes may be associated with folate
deficiency. More studies are required to confirm these results.
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CHAPTER I
INTRODUCTION
Folate is a water soluble B vitamin that has to be obtained from the diet.
Numerous disorders have been associated with folate deficiency. These include neural
tube defects (NTDs) (Smithells et al., 1976; Lucock et al., 1998), occlusive vascular
disease (OVD) (Refsum et al., 1998; Petri et al., 1996), cleft palate (Bienengraber at al.,
2001), Alzheimer’s disease (Clarke et al., 1998), Down’s syndrome (James et al., 1999),
unexplained premature births (Dekker et al., 1995), colon, breast, cervical and bronchial
cancers (Butterworth, 1993; Kamei et al., 1993; Slattery et al., 1999), and heart defects
(Tang et al., 2004; Li et al., 2005). The molecular basis for the relationship between
folate deficiency and these different conditions remains unclear.
Approximately 1 out of every 2000 births are affected by neural tube defects, the
most common, severely disabling birth defects in the United States. The most well-
known environmental cause of neural tube malformation is folate deficiency in pregnant
women (Northrup and Volcik, 2000). It is estimated that consumption of 0.4 mg of folic
acid per day by pregnant women can reduce the number of neural tube defects by 48%
(Daly et al., 1995). It has yet to be determined how folate deficiency increases the risk of
NTD’s and other developmental defects.
The goal of this study was to determine if altered folate metabolism during early
development leads to changes in the expression of selected genes. Embryos were treated
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with different concentrations of homocysteine and methotrexate, compounds known to
affect the folate pathway. Gross morphological changes, direction of the gut coiling, and
alterations in neural tube fusion were analyzed in these embryos. Using conditions
determined by this initial study, embryos treated with methotrexate and homocysteine
were analyzed for changes in gene expression by in situ hybridization. Genes used in this
study included two known to be involved in neuroectoderm differentiation and
morphogenesis, Xtwist and Pax-3, the latter of which is known to be affected by folate
deficiency (Tang et al., 2003), two genes known to be affected by folate deficiency in a
cell culture system (Dkk-1 and Wnt-5A (Katula, submitted)), and a control gene not
associated with neuroectoderm (Xbra).
This study is significant because an observed change in the expression of these
genes would suggest that folate deficiency or conditions that mimic folate deficiency can
affect the expression of specific genes. This could be the underlying cause of
developmental defects associated with folate deficiency.
Background
Folate Metabolism and Function
Folic acid or pteroylmonoglutamate is the parent structure of folates, a family of
chemically similar, highly unstable compounds. Folates facilitate the transfer of one-
carbon units from donor molecules on to various substrates of important biosynthetic
pathways, such as synthesis of thymidylate, methionine and purine, conversion of serine
to glycine, and the catabolism of histidine (Lucock, 2000). Humans can not synthesize
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folate and it must be obtained from folate rich foods including yeast extracts such as
marmite, liver, kidney, citrus fruits and leafy green vegetables.
Dietary folates, mostly existing as 5-methyltetrahydrofolate (5-methyl-THF) and
formyltetrahydrofolate (formyl-THF), are transported across the enterocyte brush border
membrane through an anion exchange anti-port transporter (Lucock et al., 1989; Herbert
et al., 1962). Polyglutamyl folates are metabolized in the liver into monoglutamyl folate,
5-methyl-THF, which is then transported in the serum to the peripheral tissues. Transport
of folate into the cells depends on two systems; membrane carriers and specific folate
binding proteins. In most cells the folate binding proteins are the primary mode of
transport. After binding of the folate to the carriers, the complex is internalized by a
nonclathrin-mediated endocytotic pathway (Birn et al., 1993).
5-methyl-THF acquired by diet or by reduction of 5,10-methylene-THF by
flavoprotein 5,10-methylenetetra-hydrofolate reductase (5,10 MTHFR) is required for the
methylation of homocysteine to methionine by vitamin B12 dependent methionine
synthase (MetSyn) (Fig. 1A). The resulting methionine can be converted into S-adenosyl
methionine (SAM) by methionine adenosyltransferase. SAM functions as a methyl donor
in a variety of reactions, including methylation of DNA and proteins (Fig. 1A).
During purine synthesis, aminoimidazole-4-carboxamide ribonucleotide (AICAR)
transformylase and glycinamide ribonucleotide (GAR) transformylase transfer a one-
carbon unit to AICAR and GAR, respectively, from 10-formyl-THF (Fig. 1B). These
one-carbon units become carbon atoms 2 and 8 of the developing purine ring. In
pyrimidine biosynthesis, the methylation of deoxyuridylate monophosphate (dUMP) by
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A) Methylation of Homocysteine to Methionine.
B) Purine and Pyrimidine Biosynthesis.
Figure 1. Folate Pathway: Folic acid is converted into different folate compounds as it
moves through the folate pathway. Methotrexate inhibits dihydrofolate reductase (DHFR)
which blocks the folate pathway from that point on (A). As a result, methylation of
homocysteine to methionine is prevented, increasing the homocysteine concentration. A
metabolite of folate pathway, 5, 10-methylene-THF, is required in purine and pyrimidine
synthesis (B).
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5,10-methylene-THF is catalyzed by thymidylate synthase (TS) to produce thymidylate
monophosphate (TMP), which is used in pyrimidine synthesis (Fig. 1B).
Clearly, the biochemical consequences of folate deficiency have broad cellular
consequences. The reduction in nucleotide precursors leads to decreased rates of DNA
synthesis and reduced DNA repair capacity and associated increases in double strand
DNA breaks (Blount et al., 1997; Duthie et al., 2000). On the other side of the pathway
(Fig. 1B), an increase in homocysteine results from lack of the metabolite 5,10-
methylene-THF and there is a decrease in the cellular level of SAM. This causes a
reduction in DNA and protein methylation reactions. Global hypomethylation and
changes in gene specific methylation have been detected in folate deficient cells (Pufulete
et al., 2003). Consequently, there is an increase in gene silencing and in some studies
increased gene expression (Lucock, 2000). Increased oxidative stress in the form of free
radicals has also been associated with excess homocysteine (Racek et al., 2005; Romerio
et al., 2005). These findings suggest that more than one mechanism is contributing to the
link between folate deficiency and different developmental defects.
Xenopus laevis as a Model System
For many years amphibians have been used in research to understand cellular,
molecular and developmental mechanisms. For numerous reasons, Xenopus laevis, the
African clawed frog, is an ideal model system for such research. These animals were first
introduced to United States in 1940s. Initially, they were used in laboratories to check for
pregnancy; injection of urine from a pregnant woman induces these frogs to lay eggs.
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Since then Xenopus laevis has become one of the predominantly used species in
embryology, as well as molecular and cellular biology (Wilt and Hake, 2004).
The Xenopus eggs are relatively large, about 1 mm in diameter, and the embryos
develop outside the animal. This permits the easy manipulation and examination of these
embryos. Because of their large size the embryo is suitable for a wide variety of
molecular and cellular techniques including in situ hybridization, single cell injection of
antibodies or RNA and cell ablation studies. Up to the first 12 cell divisions, mitosis
occurs about every 30 min, producing an embryo with over 4000 cells in 3 hours (Wilt
and Hake, 2004). As a result of their rapid development, researchers can obtain results
rather quickly. In addition, the females produce eggs in large numbers and the adult
animals are relatively easy to maintain.
All vertebrate embryos go through similar developmental stages during early
embryogenesis. It has become clear that cellular and molecular mechanisms associated
with development are conserved among vertebrate species and that proteins involved in
these pathways perform similar biological functions (Gamse and Sive, 2000). Therefore,
studies that can not be done in mammals can be carried out in lower vertebrates as a
means to understand the biology of humans. Together, these characteristics and features
make Xenopus laevis an ideal system to investigate the link between folate deficiency,
gene expression and developmental defects.
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Neurulation
Neurulation occurs during early embryogenesis of chordates and includes the
formation of the neural plate, neural folds, and the neural tube. The formation of the
neural plate starts with the induction of the neural plate or neural induction. By default,
ectodermal cells become neuroepithelium. During neural induction, a suppressive signal
produced by Hensen’s node (equivalent to Spemann’s organizer in amphibians) binds to
secreted ligands such as bone morphogenetic proteins (BMP) or Wnts and blocks their
function. This leads to suppression of the epidermal fate and formation of neuroectoderm.
As the neural plate develops, the apicobasal thickening of the ectoderm results in a flat,
thickened epithelial. This apicobasal thickening occurs as a result of cell elongation
rather than an increase in the number of cell layers (Smith and Schoenwolf, 1987; Smith
and Schoenwolf, 1988). The process of neural plate development and morphogenesis also
requires an inductive signal, sonic hedgehog (SH), produced from the underlying
notochord (Smith and Schoenwolf, 1989).
Shaping of the neural plate, driven by changes in the neuroepithelial cell behavior,
results in mediolateral narrowing and rostrocaudal elongation. On a cellular level,
shaping involves thickening, narrowing and lengthening of the neural plate driven by
neuroepithelial cell elongation (Schoenwolf and Alvarez, 1989). About half the daughter
cells produced during neurulation are destined to lengthen the neural plate rather than
widen it (Sausedo et al., 1997).
Bending, which is initiated during neural plate development, results in the
formation of the neural folds and subsequent elevation and convergence of the neural
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folds toward the dorsal midline. This occurs in two steps, furrowing and folding
(Schoenwolf and Franks, 1984). Bending of the neural plate is driven by changes in both
neuroepithelial cells (intrinsic forces) and the adjacent cells of the epidermal ectoderm
(extrinsic) (Schoenwolf, 1988; Moury and Schoenwolf, 1995). Wedging of
neuroepithelial cells is driven by changes in cell shape within the neural plate
(Schoenwolf and Smith, 1990), which causes furrowing, whereas folding of the neural
plate largely depends on extrinsic changes, which leads to the expansion of epidermal
ectoderm (Lawson et al., 2001).
Development and extension of the neural folds allows the pair of neural folds to
contact and fuse at the dorsal midline establishing the roof of the neural tube (Smith and
Schoenwolf, 1991). The neural tube then separates from the overlying epidermal
ectoderm. As a result, two separate epithelial layers are formed; epidermal ectoderm and
neuroepithelium with intervening neural crest cells. The neural crest cells arise during the
formation of the neural folds and are largely involved in the formation of the peripheral
nervous system. (Anderson, 1999; Castro and Bronner-Fraser, 1999; Groves and Broner-
Fraser, 1999; Hall, 1999; Le Douarin and Kalcheim, 1999).
Neurulation, Neural Tube Defects and Folate Deficiency
Neural tube defects (NTDs) are the most common birth defects in the United
States (Copp et al., 1990; Desesso et al., 1999; Harrist and Juriloff, 1999). Therefore it is
safe to assume that NTDs have both genetic and environmental bases. 50%-66% of these
incidents can be prevented with folic acid supplementation during early pregnancy
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(Czeizel and Dudas, 1992). Although the reasons for such preventions are unclear
(Lucock and Deskalakia, 2000), it is evident that neurulation genes are involved.
Neurulation genes are those that regulate and coordinate unique combinations of cell
behaviors in tissues involved in neurulation. 28 genes have been identified as required for
normal neurulation (reviewed by Colas and Schoenwolf, 2001). These include genes that
are involved in regulation of other genes (Cart-1, c-ski, jmj, kappa, RBP-J, Pax3,
Tcfap2a and twist), cell adhesion or its regulation (Calr, Efna5, Fkbp1a, Itga3+Itga6,
Lama5 and Pig-a), regulation of cytoskeletal dynamics (Enah, Macs, Mlp, RhoGAP5,
shrm, abl+arg and Vcl), nutrition of embryo (apoB and Folbp1) and other various
functions (Bc110, Csk, Ikk1+Ikk2, Juk1+Jnk2, Psen1+Psen2 and terc) (Colas and
Schoenwolf, 2001). Relevant to this study are Pax-3 (a transcription factor involved in
neurogenesis), twist (transcription factor expressed in neural crest) and Folbp1 (folate
acid binding protein 1).
Embryonic and fetal cells depend entirely on maternal sources of folate during
gestation. In mice, a 50% reduction of maternal liver folate was associated with a
threefold increase in the percentage of the litter affected by cleft palate (Sakanashi et al.,
1996). It was found that when placental development was impaired by folate deficiency,
the babies were small. Folate insufficiency later in pregnancy resulted in subtle birth
defects associated with neuroepithelial and neural crest cell derived structures including,
neural tube, parts of the eye and craniofacial structures (Colas and Schoenwolf, 2001).
Homozygosity for a variant of 5,10-methylenetetrahydrofolate reductase
(MTHFR), a folate pathway enzyme (Figure 1), is a genetic risk factor that results in
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about 15% of NTDs (Van der Put et al., 1997). A study done using folate receptor (FR)
knock-out and knock-down mice resulted in a high percentage of folate responsive
NTDs (Antony and Hansen, 2000). In the same study they found folate deficiency led to
the up-regulation of FRs, which implies a critical role played by FRs in folate
homeostasis (Antony and Hansen, 2000). An upregulation of FRs due to low levels of
folate resulted in reduced cell proliferation. Also, it was apparent that FRs are expressed
in both placental and embryonic tissues and play a critical role in folate uptake by the
embryo (Hansen et al., 1999). Therefore, low levels of folate increase the presence of
FRs in embryonic and placental tissues as well as decrease cell proliferation. Such a
reduction in cell proliferation of either placental, neural tube or neural crest cells could
result in serious consequences to the embryo (Antony and Hansen, 2000).
The metabolite homocysteine, which increases during folate deficiency (Allen et
al., 1993) has been identified as a risk factor for NTDs (Steegers Theunissen et al., 1994;
Van Aerts et al., 1994) and placental abruption (Wouters et al., 1993). Homocysteine
synthesis is dependent on the metabolite SAM (Figure 1). Increased homocysteine has
been shown to be associated with folate-responsive congenital heart defects and NTDs
(Rosenquist et al., 1996). The cellular accumulation of homocysteine also increases the
upregulation of FRs (Sun and Antony, 1996).
Pax-3 is expressed in closing neural folds and adjacent tissues. Although Pax-3 
mutations do not appear to be the cause of most of the NTDs seen in humans,
misregulation of the Pax-3 transcription factor which may regulate genes such as N-
CAM, N-cadherin, c-met, MyoD, Myf-5 and versican could be involved in some cases of
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NTDs. Studies on homozygous splotch (Pax-3) knock-outs have demonstrated a folate-
responsive NTD (Fleming and Copp, 1998). These NTDs seen in splotch -/- embryos are
rescued by folic acid. Interestingly these NTDs can also be rescued by thymidine.
Deoxythymidine monophosphate (dTMP) can be synthesized from deoxyuridine
monophosphate (dUMP) or thymidine. Normally, incorporation of [3H]thymidine into
dTMP is suppressed by exogenous dUMP. In homozygous splotch -/- mice the abnormal
suppression of deoxyuridine leads to the development of anencephaly and spina bifida.
These homozygous mutants incorporate significantly more [3H]thymidine into dTMP in
the absence of dUMP compared to the wild type. Administering folic acid or thymidine
to the embryo lowers the [3H]thymidine incorporation and prevents the development of
some NTDs. This demonstrates that cell specific defects can influence the embryological
process in adjacent tissues, affecting the entire cascade of development (Fleming and
Copp, 1998).
A systematic approach of looking at expression patterns of genes, which also
includes genes that are other than those folate related, is required to identify neurulation
genes that might better explain the incidence of NTDs (Stumpo et al., 1998; Melvin et
al., 2000; Joosten et al., 2001). The expression of these genes may be influenced by
folate levels in the mother and consequently the growing embryo.
Folate Deficiency and Effects on Gene Expression during Development
The relationship between folate status and increased risk of neural tube defects
such as spina bifida is well established (Lucock, 2000). The molecular mechanism by
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which folate status influences neural tube closure and other developmental events has not
been clearly determined. It has been hypothesized that the relationship between folate and
developmental defects is a reduction in cell division, particularly within rapidly dividing
cell populations of the embryo (Antony and Hansen, 2000). Surprisingly, there are
limited data supporting this idea and in some studies, no change in cell numbers were
detected (Barbera et al., 2002). As reviewed in the previous section, folate deficiency has
been shown to contribute to NTDs. There is also evidence that folate deficiency leads to
specific changes in gene expression. It has been proposed that these changes contribute to
developmental defects (Barbera et al., 2002; Tang et al., 2003; Lucock et al., 2000;
Duthie, 1999; Olshan et al., 2005).
The consequences of reduced folate in development and gene expression were
analyzed in a mouse with a knockout of the folic acid-binding protein 1 (Folbp1) gene
(Tang et al., 2003). Folbp1 is a membrane protein with a high affinity for folic acid.
Folbp1 nullizygous embryos lose the ability to transport folic acid into the epithelial
cells. In this study, expression patterns of the crucial genes such as Pax-3, En-2, Hox-a1,
Shh, and Wnt-1 were examined. Inactivating Folbp1 in mice was embryonic lethal with
severe cranial neural tube and oro-facial defects. The neural tube failed to fuse and the
mid and hindbrain remained widely open. Nullizygous Folpb1 embryos were rescued by
supplementing the diet of the pregnant heterozygous females with folic acid, indicating
that Folbp1 and folate are essential for proper embryogenesis.
Pax-3 is normally expressed from midbrain region down the entire length of the
neural tube in wild type embryos. This expression was almost absent in Folbp1
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nullizygotes embryos. En-2, essential for development of midbrain and cerebellum, is
highly expressed in the midbrain-hindbrain region of the wild type and this expression
was significantly reduced in the Folbp1 knockout embryos and was restricted to the
hindbrain region. There was no significant difference in the expression patterns of Hox-
a1 and Wnt-1 in either the wild type or nullizygous embryos. The normal expression
pattern of Shh in the neural tube from the level of the forebrain, going posterior,
expanded extensively with a high level of expression in the midbrain region of the
Folbp1 -/- mice. These results suggest that folate deficiency is altering the expression of
genes required for proper cell proliferation and differentiation (Tang et al., 2003).
In another genetic study, Cited2 deficient mice were used to test the ability of
folate to reduce exencephaly (Barbera et al., 2002). Anencephaly, a condition with many
of the same underlying causes as exencephaly is seen in births associated with folate
deficiency. Cited genes encode nuclear proteins that bind to transcriptional co-activators
and enhance transcription. Cited2-/- mutant mice die before birth and exhibited heart
defects and exencephaly. It was found that Cited2 was required for the survival of
neuroepithelial cells and its absence led to massive apoptosis in dorsal neuroectoderm
around the forebrain-midbrain boundary and in a restricted domain in the hindbrain.
When Cited2+/- pregnant females were treated daily with folic acid, the exencephaly was
reduced from 80% to 12.5% in the Cited2-/- embryos analyzed at 14.5 days post coitum.
The same type of effect was observed using embryos cultured in vitro and treated with
folic acid for 24 hours. Considering that Cited2-/- mutants revealed no defects in folate
metabolism, folic acid does not compensate for an intrinsic defect of folate metabolism in
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the embryos and they observed no reduction in the level of apoptosis or increased cell
proliferation in Cited2-/- embryos treated with folic acid. This led to the idea that folic
acid can decrease the incidence of NTDs by a mechanism other than compensating for a
folate related defect in the embryos (Barbera et al., 2002).
Decreased levels of folate result in elevated levels of homocysteine, which is
associated with neural tube defects (Afman et al., 2003). Neuroepithelial cells, cranial
neural crest cells and cardiac neural crest cells are involved in neural tube defects,
orofacial defects and conotruncal heart defects, respectively (Kirby et al., 1985;
Poelmann et al., 1998; Botto et al., 1999). Folate receptors are highly expressed in the
cells of neurectoderm, which are precursor cells of both neural crest and neuroepithelial
cells. This could explain why the beneficial effect of folic acid is specific for
neuroepithelial and neural crest cells (Boot et al., 2003). A study performed to examine
behavior of neuroepithelial cells in the presence of increased concentrations of folate and
homocysteine resulted in increased outgrowth and migration of neural crest cell from the
neural tube and inhibition of neural crest cell differentiation in the presence of
homocysteine. Addition of folic acid led to increased outgrowth of neuroepithelial cells
and neural crest cell differentiation into nerve and smooth muscle cells. This suggests that
NTDs caused by folate deficiency and hyperhomocysteinemia is due to increased
neuroepithelial to neural crest cell transformation, leading to a lower number of
neuroepithelial cells in the neural tube and a failure to close the neural tube (Boot et al.,
2003). More generally, it indicates that folate deficiency can alter cellular differentiation.
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Research Overview
Approximately 1 out of every 2000 births are effected by defects directly related
to the abnormal development of the brain, spinal chord or the improper development of
structures (heart, peripheral nervous system, skeletal and connective tissues and
endocrine tissues) derived from the neural crest cells (Wilt and Hake, 2004; Northrup and
Volcik, 2000). Many studies have shown that administering the B vitamin, folate, to the
pregnant mother reduces the prevalence of NTDs by as much as 48% (Daly et al., 1995).
Numerous genes important in the regulation of neurulation have been identified that
could be involved in NTDs (Colas and Schoenwolf, 2001). Although it has been
established that folate reduce NTDs, the underlying mechanism is unclear. Therefore, a
systematic approach based on expression patterns of genes is required to understand the
mechanisms underlying folate-related birth defects involving the neural tube. The
hypothesis guiding this project is that the developmental defects associated with folate
deficiency are due to changes in gene expression. In order to investigate this hypothesis
two specific aims need to be considered:
1. determine if methotrexate and homocysteine treatment of Xenopus embryos
can lead to developmental (neural tube and gross morphological) alterations
associated with folate deficiency.
2. analyze the spatial expression pattern of specific genes in Xenopus embryos
with altered folate metabolism and Xenopus embryos cultured in conditions
that mimic altered folate metabolism.
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CHAPTER II
MATERIALS AND METHODS
Embryo Culture
Xenopus laevis embryos prepared by in vitro fertilization and cultured in the
laboratory (Newport and Kirschner, 1982) were used in this study. Adult Xenopus laevis
were ordered from Xenopus I (Dexter, MI). Testis tissue was removed from male frogs
and cultured in oocyte culture medium [OCM: 50% Leibovitz, medium containing 15mM
N-2-hydroxyethylpiperanziner-N’-2-ethanesulfonic acid (HEPES), pH 7.8, 1 mM 1-
glutamine, 0.4 mg/ml bovine serum albumin, 1 µg/ml bovine pancreatic insulin, 100
µg/ml gentamicin sulphate, 50 U/ml nystatin]. Female frogs were injected with 600 U of
human chorionic gonadotropin (Sigma Chemical, CAT#CG-10, St. Lewis, MO) eight
hours before in vitro fertilization to stimulate ovulation. Eggs were stripped manually
from the female frogs and put in a Petri dish. Testis tissue was placed next to eggs,
smashed, and suspended in 1X Modified Barth’s Saline [MBS: 88 mM NaCl, 1 mM KCl,
2.4 mM NaHCO3, 0.82 mM MgSO4•7H20, 0.33 mM Ca(NO3)2•4H20, 0.41 mM CaCl2•6
H2O] to activate the sperm. The sperm suspension was placed onto the egg clutch and
allowed to sit for two minutes. Fertilization was initiated by adding deionized water to
eggs and testis. About 20 minutes later, when cortical rotation had occurred, water was
replaced by 2% cysteine-HCl solution (4 g of cysteine in 200 ml of H2O, pH 7.8 with
12N NaOH) to remove the jelly coat that holds the eggs together. Following the removal
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of jelly coats, the embryos were rinsed with water and cultured in 0.1X MBS at room
temperature. The developmental stages were determined according to Nieuwkoop and
Faber (1967).
As the embryos went through the first stages of cell division the most normal
appearing embryos were selected by visual examination and transferred to a new culture
dish. About 4 hours after fertilization at stage 7, the embryos were transferred into 0.1X
MBS containing different concentrations of methotrexate and homocysteine.
Preparation of compounds
To prepare 40 ml of 300 µM methotrexate in 0.1X MBS; 5.4 mg of methotrexate
(Sigma, CAT# M-9929 or Fluka, CAT# 59-05-2) was added to 2 ml of water and titrated
with 5N NaOH (approximately 5 µl) until the methotrexate dissolved. To this 2 ml
solution of methotrexate, 4 ml of 1X MBS along with 34 ml of water was added to bring
the volume up to 40 ml. Using this stock solution, dilutions were made with 0.1x MBS to
the final concentrations of 1 µM, 10 µM, 50 µM, 100 µM and 200 µM.
Stock of 370 mM concentrations of homocysteine was prepared by mixing 0.75 g
of homocysteine (Sigma, CAT# H-4628) with 15 ml of 0.1N HCl. To prepare 40 ml of
100 mM homocysteine, 10.8 ml of homocysteine stock solution was mixed with 4 ml of
1X MBS and 25.2 ml of water. The 100 mM stock was adjusted to pH 7.2 using 1N
NaOH and diluted with 0.1X MBS to prepare 0.5 mM, 1 mM, 10 mM, 25 mM and 50
mM.
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Analysis of Gross morphology, Gut Coiling and Neural Tube Thickness
Gross Morphology: Throughout development of the treated and untreated
embryos, gross morphological effects were analyzed including tail length and shape, size
of eyes, head shape and size and the presence of structural abnormalities in the gut.
Gut Coiling: At stage 45 (tadpole), about 4 days and 2 hours past fertilization
(hpf.), embryos were fixed with 4% paraformaldehyde for 1-2 hours at room temperature
and dehydrated in 100% ethanol (EtOH) to examine the direction of gut coiling under
light microscopy. The embryos were categorized according to left coiled, right coiled or
deformed as described in the results section.
Neural Tube Thickness: At stage 27 (30 hpf.) the embryos were fixed, sectioned
and stained to examine the neural tube, as described below.
Embryo Fixation, Embedding and Sectioning
Infiltration and Embedding of Embryos: Embryos were fixed with 4%
paraformaldehyde and dehydrated using an EtOH/0.1 X MBS series (25%, 50%, 75%
and 100% EtOH). Half the ethanol was replaced with Hemo-De for 5 minutes at room
temperature prior to replacing the ethanol/Hemo-De mixture twice with fresh Hemo-De
(CAT # 15 182 507A, Fisher) at 10 minute intervals. Then, half the Hemo-De was
replaced with molten paraplast (CAT # P3683, Sigma) and incubated for 10 minutes at
55˚ C before replacing the Hemo-De/ paraplast mixture with fresh paraplast and
incubating at 55˚ C for 1 hr. The paraplast was replaced twice at 30 minute intervals and
embryos were incubated at 55˚ C. Finally, the paraplast was replaced and incubated over
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night at 55˚ C. The infiltrated embryos were positioned into a mold and were embedded
in paraplast, which were allowed to harden over night at room temperature.
Slide Preparation and Subbing for Paraplast Sections: Slides were cleaned
individually with 95% EtOH and a Kimwipe and soaked in 70% EtOH for 1-2 hours. The
slide edges were blotted with a clean absorbent surface before dipping in subbing
solution (0.01% of chromium potassium sulfate added to 0.1% of gelatin in water). When
the slides were evenly coated they were tented with aluminum foil and allowed to dry.
Sectioning and Processing of Embryos: The embryos were sectioned at 11
micrometers on a microtome (Microm HM 315) and the sections were moved onto slides
coated with subbing solution. The sections were allowed to dry so the sections adhered to
the slide and washed twice in Hemo-De for 3 minutes at room temperature to remove the
paraplast from sections. The sections were hydrated using an EtOH series (100%, 75%,
50% and 25% EtOH), stained with Harris Haematoxylin for about 3 minutes, rinsed with
running water for 60 seconds and neutralized in alkaline alcohol (35% EtOH with a pinch
of sodium bicarbonate) for 1 minute. The sections were dehydrated using 70% EtOH,
counter stained with eosin in 70% EtOH for 3 minutes and the excess stain was rinsed
away with 70% EtOH. The sections were dehydrated again using an EtOH series, washed
in Hemo-D for 2 minutes before adding a drop of mounting resin and placing a cover
slip.
Analyzing the sections: The sections were observed under light microscopy and
digitally photographed using a Cannon DS 6031 camera. The thickness of the dorsal,
20
ventral and mediolateral ends of the neural tube was measured from the printed
photographs.
Analysis of Gene Expression by Whole-mount In situ Hybridization
Whole-mount in situ hybridizations were performed according to Harland (1991) with
some modifications.
Preparation of Embryos: Right after the jelly coats were removed, albino
Xenopus laevis embryos were stained with 0.01% Nile blue in 50 mM phosphate buffer,
pH 7.8 to help determine the exact developmental stage of embryos. Healthy looking
embryos were treated with 1 mM and 10 mM homocysteine and 50 µMand 100
µMmethotraxate in 0.1x MBS. Embryos were collected at stages 12 (gastrula), 20
(neurula) and 26 (tail bud). The vitelline envelopes were removed in some of the stage 20
and stage 26 embryos. Embryos were fixed in fresh MEMFA buffer (0.1 M 3-[N-
morphlino] propanesulfonic acid (MOPS), pH 7.4, 2 mM EGTA, 1 mM magnesium
sulfate (MgSO4), 3.7% formaldehyde) with gentle agitation at room premature for 1-2
hours. Following fixation, embryos were dehydrated with methanol (MeOH) and stored
at -20º C.
Probe Synthesis: pBluescript Plasmids containing cDNAs coding for Xenopus
Dkk-1 (pRNDkk-1), Wnt-5A (pBSXE3), Pax-3 (Pax3 D2), Xbra (pXbrachyury) and
Xtwist (pXtwist) were linearized with appropriate restriction enzymes such that sense and
anti-sense transcripts can be generated using T3, T7 or Sp6 RNA polymerase as
appropriate (Table 1).
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The volume of the digested DNA sample was increased up to 100 µl with
diethylpyrocarbonate (DEPC) treated H2O. To the above mixture, an equal volume of
phenol chloroform was added, vortexed and spun for 5 min at 16000 x g. Then, the
supernatant was transferred to a new tube and an equal volume of chloroform was added
to the supernatant. The mixture was centrifuged again for 5 min at 16000 X g and
supernatant was removed to a clean tube. 0.1X volume of 3M NaAcetate and 2X volume
of absolute EtOH was added to the supernatant and the mixture was vortexed before
placing it at -20° C overnight. The next day, the DNA mixture was centrifuged for 10
min at 16000 X g, EtOH removed, 100 µl of 70% cold EtOH was added and centrifuged
for 5 min at 16000 X g. The supernatant was removed and the DNA pellet was air dried
prior to resuspending in 20 µl of DEPC ddH2O. In order to synthesize the RNA probe,
2.5 µg of linearized template DNA was added to a mixture containing 1X transcription
buffer, 10 mM DTT, 1% RNAsin, 60 units of the appropriate RNA polymerase, rNTP
mix [2.5 mM CTP, GTP, ATP, 1.6 mM UTP and 0.9 mM digoxygenin (dig) -UTP
(Boehringer-Mannheim Biochemical, CAT# 209256)] and DEPC treated H2O. The
reaction was incubated at 37° C for 2 hrs and DNAse was added to each sample to
eliminate template DNA. The samples were centrifuged through a G-50 spin column to
remove unincorporated nucleotides from the synthesized RNA (Eppendorf-5 Prime,
CAT# 3-337047, Boulder, CO). To the RNA sample, 0.1X volume of 3 M NaAcetate
with 2.5X volume of 100% EtOH was added and the sample was stored at -80° C
overnight or longer. The precipitated RNA was pelleted by centrifuging the sample at 4°
C, 16 000 X g for 10 min. The supernatant was removed, 500 µl of 70% EtOH was added
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to the RNA pellet and the sample was centrifuged for 5 min at 40 000 xg. The sample
was air dried and resuspented in 200 µl of hybridization buffer [0.1% CHAPS, 1X
Denhart’s, 5 mM EDTA, 50% formamide, 100 ug/ml Heparin, 5X sodium citrate (SSC),
0.5 mg/ml Torula RNA, 0.1% Tween-20 and DEPC treated H2O. The probe stocks were
stored at -80° C until use.
Hybridization of Embryos with RNA Probes: 0.5 volume of DEPC H2O was
added every 5 minutes to the embryos stored in 100% MeOH until the MeOH
concentration reached 25%. The embryos were then washed thoroughly with PBST [1X
phosphate-buffered saline (PBS) and 0.1% Tween-20] five times for 5 minutes each time.
The embryos that had been fixed with the vitelline membrane intact (stage 12) were
incubated in proteinase K (10 µg/ml), collagenase A [2 mg/ml (Roche, CAT# 103 578)]
and hyaluronidase [20 U/ml (Sigma, CAT# H-4272)] for 10 minutes at room temperature
to remove the vitelline membrane and to permeabilize the embryos. Embryos that had
hatched or with removed vitelline membrane were incubated in proteinase K at room
temperature for 15 minutes. Embryos were then washed in PBST three times for 5
minutes to remove the proteinase K, followed by two 5 minute washes in 0.1 M
Triethanolamine (TEA). In order to prevent electrostatic interactions between probe and
basic proteins, 10 µl of acetic acid anhydride was added twice, at 5 minute intervals to
each vial containing 4 mls of 0.1 M TEA. Following neutralization, the embryos were
washed twice in PBST, refixed in 4% paraformaldehyde in PBST for 20 minutes, washed
5 times in PBST and transferred into 20 % hybridization buffer/80% PBST. These
embryos were pre-hybridized over night at 60° C in hybridization buffer. The next day, 1
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ml of hybridization buffer containing ~2 µg of probe was added to each vial and embryos
were incubated over night at 60° C. Prior to adding Dig-labeled RNA probes, the
probe/hybridization buffer mixture was incubated at 75º C for 5 minutes to denature the
probe. Following hybridization, the probe was removed and stored at -80˚ C to be re-
used. The embryos were washed with hybridization buffer for 10 minutes at 60˚ C,
followed by four 20 minute washes in 2X sodium citrate (SSC) (20X SSC: 3 M NaCl and
0.3 M Na citrate, pH to 7.6 with HCl) and a high-stringency wash for 1 hr in 0.2X SSC at
60˚ C. Then, the embryos were incubated in a 1X maleic acid buffer (MAB) (5X MAB:
0.5 M maleinic acid and 0.75 M NaCl), pH 7.5, containing 2% Boehringer-Mannheim
Blocking Reagent (BMBR) (Roche, CAT# 1096176) at room temperature followed by
two consecutive 15 minute washes in 1X MAB at 60˚ C and room temperature. Next, the
embryos were blocked for 1 hr at room temperature in 0.9 ml of blocking buffer lacking
antibody (MAB containing 20% heat inactivated lamb serum and 2 % BMBR). The
blocking buffer was removed and replaced with 0.1 ml of blocking buffer containing
anti-dig antibody (Boehringer-Mannheim Biochemical, CAT# 1093274, Germany)
diluted 1:2000 and incubated overnight at 4˚ C. The next day, the embryos were
thoroughly washed with four 1 hr washes at room temperature in 1X MAB and then
incubated in 1X MAB overnight at 4˚ C. The embryos were equilibrated with two 5
minute washes in alkaline phosphatase (AP) buffer [100 mM Tris (pH 9.5), 50 mM
MgCl2, 100 mM NaCL, 0.1% Tween-20 and 5 mM Levamisol] at room temperature
before adding 1 ml of BM Purple AP substrate (Roche, CAT# 1442074) to start the color
reaction. The staining reaction was kept in dark for 5-6 hrs at room temperature to
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achieve the proper level of staining. The stained embryos were washed thrice with 1X
PBS for 5 minutes at room temperature. The color reaction was stopped by two 30 minute
washes at room temperature in MEMFA. The embryos were then dehydrated in methanol
and examined under bright field microscopy. The images were captured using a Olympus
PM-C35DY and processed using Adobe Photoshop 7.0. Some embryos were bleached to
reduce the background staining by incubating overnight at 4˚ C in 2:1 MeOH/H2O2 under
high light. Also, some embryos were cleared to allow for examination of internal staining
in 1:2 Benzyl Alcohol/Benzyl Benzoate (BA/BB) solution until the embryos sank to the
bottom of the vial.
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CHAPTER III
RESULTS
Development of Embryos Treated with Homocysteine and Methotrexate
The Xenopus embryo is an ideal system to investigate the link between the effects
of folate deficiency and associated developmental defects because the embryos are
readily available and there is extensive knowledge of the morphological and molecular
details of development. One problem, however, is the inability to deplete the folate
naturally present in the egg and available to the growing embryo. As an alternative, I
chose to simulate effects of altered folate metabolism by treating growing embryos with
methotrexate and homocysteine. Methotrexate inhibits an enzyme in the folate pathway,
dihydrofolate reductase (Figure 1). Consequently, the central folate pathway is blocked
leading to a reduction in 5, 10, methylene–THF and 5-methyl–THF, the folate
intermediates required for deoxythymidine monophosphate (dTMP) and methionine
biosynthesis, respectively. Homocysteine is a naturally occurring amino acid that is
methylated to produce methionine. When 5- methyl–THF is not generated there is a
decreased conversion of homocysteine to methionine and corresponding increase in
homocysteine. Thus, addition of homocysteine is expected to mimic, in part, folate
deficiency in the embryo.
For these initial studies we examined the gross morphology (overall development,
size of the head, length of the body, size of the eyes and direction of gut coiling) and
27
neural tube of homocysteine and methotrexate treated embryos. Methotrexate treatment
has also been shown to result in randomization of the direction of gut coiling in Xenopus
embryos (Bantle et al., 1990). Therefore, direction of gut coiling was categorized in
Xenopus embryos that had been grown in different concentrations of methotrexate and
homocysteine. A similar effect on gut coiling would suggest a suitable concentration of
methotrexate and homocysteine to use in these studies and also that homocysteine and
methotrexate lead to a similar morphological end point.
Xenopus Development and Gross Morphological Defects
Homocysteine
Xenopus embryos were grown in different concentrations (0.5 mM, 1 mM, 10
mM, 25 mM, 50 mM and 100 mM) of homocysteine and their gross morphology was
compared (Figure 2). No difference in development or morphology was observed up to
gastrula stage (stage 12). Embryos treated with 100 mM homocysteine did not develop
beyond the gastrula stage. By stage 23, some embryos treated with 10 mM homocysteine
were underdeveloped compared to the controls. By stage 41 it was evident that the
embryos treated with 10 mM and 50 mM were exhibiting developmental defects, such as
kinked bodies, underdeveloped guts, small eyes or were generally deformed compared to
untreated embryos. However, at concentrations of 10 mM and above, there were some
embryos that exhibited normal development within the same group of embryos. At stage
45 (tadpole stage) the developmental defects in embryos treated with 10 mM and 50 mM
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were obvious with smaller and kinked bodies and deformed internal structures. In
particular, the guts were severely deformed or miscoiled.
Methotrexate
Xenopus embryos were grown in different concentrations (1 µM, 10 µM, 50 µM,
100 µM and 200 µM) of methotrexate and their gross morphology was compared (Figure
3). By the time control embryos reach stage 26, 1 µM, 10 µM and 50 µM methotrexate
treated embryos included individuals with different developmental stages, ranging from
stage 24-26. At 100 µM, the developmental stages of the embryos varied from stages 12-
26 and some of the embryos did not survive beyond stage 12 (gastrula). In each set of
treated embryos, there were embryos with deformities such as small eyes, deformed and
kinked bodies and underdeveloped or missed coiled guts. Although the severity of the
deformities increased as the methotrexate concentration increased, some of the embryos
even above 100 µM showed normal development.
Survival and Direction of Gut Coiling
The embryonic gut is derived from the endodermal germ layer. Development of
Xenopus laevis gut starts 3 days past fertilization (Chalmers and Slack, 1998; Chalmers
and Slack, 2000). Previous studies have shown that randomization of gut coiling occurred
due to teratogens (Bantle et al., 1990; Vismara et al., 2000) and changes in gene
expression (Branford et al., 2000). In particular, adding methotrexate has resulted in
randomization of the Xenopus gut along with defects such as microopthalmia,
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micoencephaly and hydroencephaly, in neuroepithelial derived structures (Bantle et al.,
1990). Therefore, during this study I looked at direction of gut coiling in embryos treated
with homocysteine and methotrexate to establish concentrations that is able to cause a
detectable effect without killing or severely deforming the embryos.
Homocysteine
In conjunction with this study, I recorded general morphology, survival and the
direction of gut coiling of treated and untreated embryos at stage 45. Table 2 is a
combination of those data from two separate experiments. Percent mortality for embryos
treated with 0.5 mM, 1 mM, 10 mM and 50 mM homocysteine remained between 12%-
15%, while untreated embryos had a percent mortality of 7%. In contrast, embryos
treated with 100 mM homocysteine did not survive past gastrula stage with a percent
survival of 0%. An embryo with two heads was observed at 0.5 mM concentration. At 10
mM homocysteine, live embryos without a gut and an embryo that did not show any
structural development was observed. It was evident that the severity of the deformities
increased with the increased homocysteine concentrations.
The data for percent coiling to the left and right and percent of embryos with
deformed or miscoiled guts are shown in figure 4. Examples of embryos with left, right
and miscoiled guts are shown in figure 5. In this experiment, the majority of the guts
were coiled to the left in the untreated embryos (Figure 4). As the concentration of
homocysteine increased the guts coiling to the left decreased, the number of deformed or
miscoiled increased and there was a net increase in the number of guts coiling to the
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Table 2. Survival, General Appearance and Gut Coiling of Homocysteine Treated
Embryos.
Experiment 1
Concentration of
Homocysteine
# of Embryos
Survived
# of guts
Deformed
# of guts coiled
to left
# of guts coiled
to right
Control 23 1 (4.3%) 21 (91.3%) 1 (4.3%)
0.5 mM 33 2 (6.1%)
1 underdevel.
26 (78.8%)
1 underdevel.
5 (15.2%)
1 mM 31 4 (12.9%) 23 (74.2%) 4 (12.9%)
10 mM 23 13 (56.5%)
5 no gut
1 (4.3%) 9 (39.1%)
Experiment 2
Concentration of
Homocysteine
# of Embryos
Survived
(Out of 40)
# of guts
Deformed
# of guts coiled
to left
# of guts coiled
to right
Control 1 38 4 (10.5%) 18 (47.4%)
1 underdevel.
16 (42.1%)
3 underdevel.
Control 2 37 1 (2.7%) 25 (67.6%) 11 (29.7%)
3 underdevel.
0.5 mM 1 30 4 (13.3%)
1 underdevel.
22 (73.3%) 4 (13.3%)
0.5 mM 2 38 4 (10.5%)
1 underdevel.
1 two headed
24 (63.2%) 10 (26.3%)
2 underdevel.
1 mM 1 35 1 (2.9%) 20 (57.1%) 14 (40%)
1 underdevel.
1 mM 2 36 2 (5.6%)
1 underdevel.
26 (72.2%) 8 (22.2%)
2 underdevel.
10 mM 1 36 8 (22.2%)
2 underdevel.
20 (55.6%)
1 underdevel.
9 (25%)
1 underdevel.
10 mM 2 35 22 (62.9%)
-1 alive but no
cell differentiated
9 (25.7%) 4 (11.4%)
50 mM 1 35 35 (100%) 0 (0%) 0 (0%)
50 mM 2 34 34 (100%) 0 (0%) 0 (0%)
100 mM 1 0 0 0 (0%) 0 (0%)
100 mM 1 0 0 0 (0%) 0 (0%)
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For experiment 1, 25-35 embryos were treated with each concentration of homocysteine.
During experiment 2, two groups of 40 embryos were treated with 0 mM, 0.5 mM, 1
mM, 10 mM, 50 mM and 100 mM concentration of homocysteine. The embryos were
scored at stage 45 (~98 hpf). Underdeveloped (underdevel.) refer to embryos with gut
coiling patterns more similar to stages 43 -44 than stage 45.
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Figure 5. Examples of Gut Coiling. Embryos treated with homocysteine and
methotrexate were fixed at stage 45 (~98 hpf.) to examine the direction of the gut coiling.
The embryos were categorized according to right coiled (A), left coiled (B) and deformed
or mis-coiled (C, D and E).
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right. At 0 mM ~92 % were left coiled and ~5 % were right coiled. At 10 mM these
values were ~5 % and 38 %. There is a substantial increase in the deformed guts and a
change in the direction of gut coiling as the concentration of homocysteine increased
from 0 mM to 10 mM. All the embryos at 50 mM had deformed guts. The embryos with
an underdeveloped gut coiling pattern had a coiling pattern that was more similar to
embryos of stage 43 through stage 44 than stage 45.
Methotrexate
Out of 45 embryos the number of methotrexate treated embryos surviving to stage
45 was determined (Table 3 and Table 4). The percent mortality of embryos treated with
0 µM, 1 µM, 10 µM, 50 µM, 100 µM and 200 µM methotrexate was 1.7%, 8.3%, 3.9%
4.4%, 8.9% and 4.4%, respectively. Though there is an increase in mortality as the
concentration of methotrexate increased, the number of embryos surviving at 1 µM was
higher than expected. Some embryos within the untreated group were underdeveloped
and the number of underdeveloped embryos increased slightly in higher methotrexate
concentrations. Also, the number of deformed embryos and the severity of the
deformities increased as the concentrations of methotrexate increased. These deformities
included kinked bodies, very thin and small bodies and embryos lacking properly defined
head structure or trunk structure.
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Table 3. Survival and General Appearance of Methotrexate Treated Embryos.
Two groups (1 and 2) of 45 embryos each were treated with the indicated concentrations
of methotrexate. The embryos were scored at stage 45 (~98 hpf). Underdeveloped
(underdev.) refer to embryos that had an overall morphology of a stage earlier than stage
45.
Concentration of
Methotrexate
# of Embryos
Survived (Out
of 45)
# with Significant Morphological Abnormalities
Control 1 45
Control 2 44
1 µM 1 41 1 very small and deformed and dead.
1 deformed but alive
1 µM 2 41 1 deformed but alive
10 µM 1 42 1 very kinked and alive
1 severely deformed and barely alive.
10 µM 2 44
50 µM 1 44
50 µM 2 42
100 µM 1 40 2 severely badly deformed, but alive
100 µM 2 42 2 severely deformed and dead
2 severely deformed but alive, appear to be parts
of embryos
200 µM 1 44 1 underdev. and dead
200 µM 2 42 1 underdev. and dead
38
Table 4. Gut Coiling and the Appearance of Methotrexate Treated Embryos.
Two groups (1 and 2) of 45 embryos each were treated with the indicated concentrations
of methotrexate. The embryos were scored at stage 45 (~98 hpf) according to their gut
orientation. Underdeveloped (underdev.) refer to embryos with gut coiling patterns more
similar to stages 43-44 than stage 45. In some cases the direction of coiling in
underdeveloped embryos could be determined.
¹ dev = developed.
Concentration
of Methotrexate
Number of
Embryos
(Out of 45)
Number of Guts
Deformed
Number of Guts
Coiled to Left
Number of Guts
Coiled to Right
Control 1 45 7 (15.5%)
- 2 underdev.
- 1 small eyed
28 (62.2%)
- 1 very short
10 (22.2%)
- 5 underdev.
Control 2 43 7 (16.3%)
- 1 coiled inward
- 2 underdev.
28 (65.1%)
- 2 underdev.
8 (18.6%)
- 2 underdev.
1 µM 1 42 10 (23.8%)
- 2 underdev.
14 (33.3%)
- 1 underdev.
18 (42.9%)
- 8 underdev.
1 µM 2 41 6 (14.6%) 30 (73.2%) 5 (12.2%)
10 µM 1 42 12 (28.6%)
- 5 underdev.
14 (33.3%)
- 4 underdev.
16 (38.1%)
- 8 underdev.
10 µM 2 45 7 (15.5%)
- 2 hardly dev.¹
- 1 no gut formed
22 (48.9%) 16 (35.5%)
- 5 underdev.
50 µM 1 44 5 (11.4%)
- 4 underdev.
24 (54.5%)
- 5 underdev.
15 (34.1%)
- 5 underdev.
50 µM 2 42 3 (7.1%) 38 (90.3%) 11 (26.2%)
- 3 underdev.
100 µM 1 42 20 (47.6%)
- 1 underdev.
15 (35.7%) 7 (16.7%)
100 µM 2 44 33 (75%)
- 5 underdev.
9 (20.5%)
- 8 underdev.
2 (4.5%)
- 2 underdev.
200 µM 1 44 38 (86.4%)
- 7 underdev.
3 (6.8%)
- 3 underdev.
3 (6.8%)
- 2 underdev.
200 µM 2 43 19 (44.2%)
- 3 underdev.
15 (34.9%)
- 2 underdev.
9 (20.9%)
- 3 underdev.
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The direction of gut coiling was assessed in embryos cultured in the presence of
methotrexate. The data for percent of embryos with deformed or miscoiled guts, guts
coiling to the right and the guts coiling to the left are shown in figure 6. The majority of
the untreated embryos had guts coiling to the left and there is a net decrease in the
number of embryos with guts coiling to the left as the concentration of methotrexate
increased with the exception of 50 µM. There is also a net increase in the percent of
embryos with deformed or miscoiled guts as the concentrations increase with the
exception of 50 µM. The percent of guts coiling to the right increased from 21% to 37%
as the concentration of methotrexate increased from 0 µM to 10 µM respectively, then
decreased to 14% at 200 µM. The treated embryos that showed underdeveloped guts had
a coiling pattern that was more similar to embryos of stages 43 through stage 44 than
stage 45. The decrease seen in right coiling guts could be due to the increase in deformed
or mis-coiled guts.
Neural Tube Thickness of Treated Embryos
It is well known that folate deficiency leads to neural tube defects, such as the
failure of neural tube to close properly and anencephaly (Lucock, 2000). On a gross
morphological level, we could not detect unclosed neural tubes in homocysteine and
methotrexate treated embryos surviving to stage 27. To examine the structure of the
neural tube in more detail the neural tube thickness was measured in homocysteine and
methotrexate treated embryos. Treated embryos were infiltrated, embedded, sectioned
and stained. Sections were examined at the level of first appearance of the ears. Four
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measurements of the neural tube were taken at the dorsal (A), ventral (D) and
mediolateral (B and C) as shown in figure 7.
Homocysteine
Figure 8 shows the average measurements of the thickness of the neural tube
obtained at each of the above mentioned locations. Mediolateral sides were the thickest
part of the neural tube while the dorsal side was the thinnest. At a homocysteine
concentration of 25 mM, the dorsal side was considerably thinner (1.08 mm) compared to
other concentrations and untreated embryos (4.13 mm). However, there does not seem to
be any particular relationship between neural tube thickness and homocysteine
concentration.
Methotrexate
Neural tube thickness in relation to methotrexate concentrations is shown in
figure 9. There is a substantial decrease in the thickness of the dorsal side as the
concentration of methotrexate increases. The average thickness of the dorsal side in the
untreated embryos was 5.88 mm, whereas in the embryos treated with 200 µM
methotrexate, this value was 2.71 mm. Also, there appears to be an increase in the
thickness of the ventral side of the neural tube with increasing amounts of methotrexate
(at 0 µM – 4.2 mm and at 200 µM – 5.5 mm). The thickness of the mediolateral sides
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Figure 7. Analysis of the Neural Tube. Embryos treated with homocysteine and
methotrexate were sectioned at stage 27 (~30 hpf.) and the neural tube was measured at
dorsal (A), ventral (D) and mediolateral (B and C) widths.
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remained about the same regardless of the methotrexate concentrations. In general, these
embryo sections were of higher quality.
Gene Expression Patterns in Xenopus Embryos with Altered Folate Metabolism
Studies completed in this laboratory and at the National Institute of
Environmental Health Sciences have shown that folate deficiency in cultured human
fibroblast cells leads to alterations in the expression of genes, including those involved in
the Wnt pathway. The Wnt signaling pathway controls patterning and cell fate
determination during development (Wilt and Hake, 2004). It has been shown to be
involved in the differentiation of the nervous system, skeletal muscles, cardiac cells,
endoderm, cartilage and limbs (Gregory et al., 2003). Dkk-1 is an inhibitor of the
canonical Wnt / beta-catenin signaling pathway and Wnt-5A is a positive activator of the
pathway. Since both genes have been shown to be involved in Xenopus development it is
possible that Dkk-1 and Wnt-5A expression is altered in Xenopus embryos due to altered
folate metabolism. In addition, we examined the expression of Xtwist and Pax-3 genes.
These genes are known to be involved in neural tube formation and there is evidence that
Pax-3 is linked in some way to the folate pathway (Tang et al., 2003). The gene Xbra
served as a negative control since it is a mesodermally expressed gene involved in
gastrulation. The functions of all the genes used in this study and their embryonic
patterns of expression are listed in Table 1.
Embryos were treated with 10 mM homocysteine and 100 µM methotrexate and
collected at stage 12 (gastrula), stage 20 (neurula) and stage 26 (tail bud). Whole-mount
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in situ hybridization reactions were performed using different riboprobes according to
table 1. Results for each gene were analyzed individually.
Pax 3
Pax-3 is a transcription factor which plays critical roles during neurogenesis
(Takahashi et al., 1992). Untreated and treated (10 mM homocysteine and 100 µM
methotrexate) embryos were grown to stage 12 (gastrula), a developmental stage where
Pax-3 expression pattern can be visualized as two patches situated at lateral ends of the
embryo in the presumed site of the neural plate (Table 1). The level and pattern of
staining in both untreated and homocysteine treated embryos were similar with two
defined lateral patches at the dorsal side. The pattern of Pax-3 expression in methotrexate
treated embryos was similar in location to those of untreated embryos, but the staining
was not restricted to a defined patch, rather spread from anterior to mid posterior (Figure
10). The expression pattern in cleared embryos did not seem any different from uncleared
methotrexate embryos, but the level of Pax-3 staining in homocysteine treated cleared
embryos appeared diminished in comparison to untreated (figure 10). At higher
magnification the above expression patterns were confirmed and the reduced level of
hybridization in the homocysteine treated embryos is more apparent (Figure 11).
Dkk 1
Dkk-1 encodes a secreted protein which is required for head formation (Glinka et
al., 1998). Untreated and treated (10 mM homocysteine and 100 µM methotrexate)
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embryos grown to stage 12 were used to examine Dkk-1 expression pattern. The pattern
can be visualized at the anterior end with two streaks extending dorsally (Table 1). The
treated and untreated embryos displayed a very weak staining pattern in the expected
region (Figure 12) in comparison to the published data (Glinka et al., 1998). It is likely
that our embryos were at an earlier stage as evident by the large blastopore in comparison
to that seen in Dkk-1 stained embryos in table 1. However, it appeared that the staining
was darker in untreated embryos compared to homocysteine and methotrexate treated
embryos (Figure 12). Examining cleared embryos under higher magnification verified
these findings (Figure 13). Moreover, it appeared that the level of expression in
homocysteine was less than methotrexate. These results suggest that Dkk-1 transcript
levels are reduced in methotrexate and homocysteine treated embryos.
Xtwist
Xtwist is a transcription factor expressed in the neural crest (Hopwood et al.,
1989). The treated (10 mM homocysteine and 100 µM methotrexate) and untreated
embryos were grown to stage 26 to examine Xtwist expression pattern. Xtwist is known to
be expressed in neural tube, notochord, four cranial neural crests (mandibular, hyoid,
anterior and posterior bronchial crest), somites and neural crest cells, (Table 1).
Comparing the treated (homocysteine and methotrexate) and untreated embryos, there
appears to be no difference in the expression pattern. The pattern was prevalent in the
neural tube, somites and head crests. But in some untreated embryos, the somites seem to
be stained less than the treated embryos. It was difficult to compare these embryos as the
50
F
ig
ur
e
12
.E
xp
re
ss
io
n
P
at
te
rn
of
D
kk
-1
in
T
re
at
ed
an
d
U
nt
re
at
ed
E
m
br
yo
s.
In
si
tu
hy
br
id
iz
at
io
n
w
as
pe
rf
or
m
ed
on
tr
ea
te
d
(
10
m
M
ho
m
oc
ys
te
in
e
an
d
10
0
µ
M
m
et
ho
tr
ex
at
e)
an
d
un
tr
ea
te
d
em
br
yo
s
at
st
ag
e
12
(g
as
tr
ul
a)
us
in
g
a
D
kk
1
ri
bo
pr
ob
e.
E
m
br
yo
s
w
er
e
an
al
yz
ed
by
li
gh
tm
ic
ro
sc
op
y.
T
he
to
p
pa
ne
ls
ho
w
s
em
br
yo
s
th
at
ar
e
un
cl
ea
re
d
an
d
bo
tt
om
pa
ne
l
in
cl
ud
es
em
br
yo
s
cl
ea
re
d
in
B
B
/B
A
.A
rr
ow
s
in
di
ca
te
ar
ea
s
of
sp
ec
if
ic
st
ai
ni
ng
.
51
F
ig
ur
e
13
E
xp
re
ss
io
n
P
at
te
rn
of
D
kk
-1
in
T
re
at
ed
an
d
U
nt
re
at
ed
E
m
br
yo
s
U
nd
er
H
ig
h
M
ag
ni
fi
ca
ti
on
.
S
am
e
as
in
fi
gu
re
#
bu
tu
nd
er
hi
gh
er
m
ag
ni
fi
ca
ti
on
,1
00
x.
52
expression pattern is quite complicated (Figure 14 and 15).
Xbra
Xbra is a mesodermal transcription factor involved in regulating early Hox
expression (Smith et al., 1991). To examine the Xbra expression pattern 10 mM
homocysteine and 100 µM methotrexate treated and untreated embryos were grown to
stage 12 (11 hpf). Since XBra is a mesodermal transcription factor, the normal pattern is
displayed within the mesoderm cells surrounding the blastopore (Table 1). XBra
expression level and pattern in the homocysteine treated embryos was uniform and
similar to the untreated controls. Though the methotrexate treated embryos also stained
around the yolk plug, the expression pattern included an extension , the notochord,
(Figure 16 and 17 arrows ) and the staining level was less, which is more evident in the
cleared embryos (Figure 16 and 17). However, the pattern was slightly different and the
yolk plug was considerably smaller compared to the untreated and homocysteine treated
embryos. These observations indicate that the methotrexate treated embryos were a later
gastrula stage, compared to the untreated and homocysteine treated embryos.
Wnt-5A
Wnt-5A encodes secreted signaling proteins involved in axis induction (Moon et
al., 1999). Homocysteine and methotrexate treated embryos were grown to stage 20
(neurula) to analyze Wnt-5A expression pattern. The treated (10 mM homocysteine and
100 µM
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methotrexate) and untreated embryos showed staining alone the length of the neural tube
(results not shown). Due to the inconsistent results achieved through the in situ
hybridization protocol used at the time, these results were considered inconclusive and
are not included.
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CHAPTER IV
DISCUSSION
Approximately 1 out of every 2000 births are affected by neural tube defects in
the United States. The most well-known environmental cause of neural tube
malformation is folate deficiency in pregnant women (Northrup and Vocik, 2000).
Although it has been established that administering folate to the pregnant mother reduces
the prevalence of NTDs by as much as 48% (Daly et al., 1995), the underlying
mechanism is unclear. Therefore, a systematic approach based on expression patterns of
genes is required to understand the mechanisms underlying folate-related birth defects.
The goal of this study was to determine if altered folate metabolism during early
development leads to changes in the expression of selected genes.
Xenopus laevis embryos were treated with different concentrations of
homocysteine and methotrexate and their gross morphology including direction of gut
coiling and neural tube thickness was analyzed. In situ hybridization was performed in
treated and untreated embryos to analyze changes in expression patterns of the genes
Dkk-1, Pax-3, XBra, Xtwist and Wnt-5A. It was evident that treatment with homocysteine
and methotrexate lead to developmental defects consistent with folate deficiency. Gene
expression patterns of Xbra and Xtwist was not affected by folate deficiency while Dkk-1 
and Pax-3 expression appeared to be down regulated.
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Homocysteine and Methotrexate Cause Morphological Defects and Delayed
Development
It is not possible to deplete the folate naturally present in the egg, thus available to
the growing embryo. In order to overcome this problem, we attempted to alter folate
metabolism and mimic low levels of folate using the compounds methotrexate and
homocysteine, respectively. Methotrexate inhibits the folate pathway enzyme,
dihydrofolate reductase. As a consequence, there is a reduction in dTMP and methionine
biosynthesis and an associated increase in homocysteine (Figure 1). The increased levels
of homocysteine which are associated with NTDs, cancer, heart conditions and
Alzheimer disease (Ernest et al., 2002) mimic the conditions of blocking the folate
pathway.
To assess the effects homocysteine and methotrexate have on Xenopus
development, we examined gross morphology, gut coiling and neural tube thickness. In a
previous study, methotrexate treatment of Xenopus embryos caused mis-coiling of the
gut, microopthalmia, microencephaly and hydroencephaly (Bantle et al., 1990). In chick
embryos homocysteine treatment of chicken embryo lead to heart and neural tube defects
(Afman et al., 2003). And, mouse embryos lacking the Folbp1 were found to have severe
developmental defects including small embryos, a fewer number of somites, failure of the
neural tube to fuse cranially and disruptions in palate formation (cleft palate) and upper
lip (cleft lip). Also, Folbp1 nullizygosity was found to be lethal as these embryos died in
utero around gestational day 10 (Tang and Finnell, 2003; Piedrahita et al., 1999). Based
on these findings, we expected homocysteine and methotrexate treated Xenopus embryos
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would exhibit similar morphological defects to that of folate deficient embryos as
detected in these studies.
We found that homocysteine at higher concentrations was capable of arresting
development at or around the time of gastrulation. When analyzing later stage embryos it
was evident that homocysteine slowed the development of these embryos and caused
numerous deformities such as small eyes, small bodies, kinked backs and gut deformities.
Embryos treated with methotrexate exhibited similar morphological abnormalities. The
percent mortality in homocysteine treated embryos ranged between 12 % - 15 %, whereas
untreated remained at 7%. Methotrexate treated embryos had a percent mortality ranging
from 3.9 % - 8.9%. The untreated embryos in the methotrexate had a percent mortality of
1.7%. It was evident homocysteine and methotrexate caused percent mortality to double
in treated embryos compared to untreated. But, there did not appear to be a correlation
between higher concentration and increased mortality. These results indicate both
homocysteine and methotrexate effect development in a manner similar to that observed
in development of other organisms subjected to compromised folate metabolism.
Guts in Xenopus start to coil at stage 41. By stage 45 the gut has acquired the
proper coiling orientation. The gene FoxF1 was found to be important in gut coiling and
orientation. FoxF1 is expressed in lateral plate mesoderm and later in visceral mesoderm.
The absence of this gene has resulted in lack of proliferation and differentiation of the
lateral plate and visceral mesoderm cells and impaired gut morphogenesis (Tseng et al.,
2004). Furthermore, Xnr-1, XPitx2 and homeobox genes Pdx1 and Cdx2 are also found to
be involved in gut morphogenesis (Beck, 2002). Methotrexate treatment has been shown
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to result in randomization in the direction of gut coiling Xenopus embryos (Bantle et al.,
1990). One possibility is that methotrexate is affecting the expression of one or more of
the genes listed above.
In our study of the effects of homocysteine on gut coiling most of the untreated
embryos had a left coiled pattern and as the concentration of homocysteine increased the
percent coiling to the left decreased. This was due both to an increase in the number of
guts coiling to the right and the number of with deformed or mis-coiled guts.
Methotrexate treated embryos showed similar effects with the increase of mis-coiled or
deformed guts and decrease of guts coiling to the left as the concentration of
methotrexate increased. The guts coiling to the right increased up to 10 µM methotrexate
and then at higher concentrations decreased. It is hard to explain why at 50 µM
methotrexate the number of guts coiling to the left increased dramatically while the
number of deformed guts decreased. This very well could be due to an error in scoring
such that right coiling guts were recorded as left.
Neurulation in chordates includes the formation of neural plate, neural folds and
neural tube. The neural tube will develop into the future brain and spinal cord. The neural
plate forms as a central strip of surface ectoderm cells, just above notochord. These cells
gradually fold inward, forming neural folds and eventually breaks free of the surface
ectoderm. The closing process of neural tube is very critical as defects in closure may
results in spina bifida and other NTD (Colas and Schoenwolf, 2001). The most well
known environmental cause of neural tube malformation is folate deficiency in pregnant
women (Northrup and Volcik, 2000). Nullizygous Folbp1 mice were found to have NTD
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and craniofacial abnormalities such as cleft lip and cleft palate (Tang and Finnell, 2003).
The defects in the neuroepithelium include lack of formation of the forebrain or optical
vesicles, reduced thickness of neuroepithelium to only a couple of cells layers, altered
migration of neural crest cells and lack of neural tube fusion (Piedrahita et al., 1999).
Analyzing the gross morphology of treated and untreated Xenopus embryos, we did not
observe any embryos with defects in neural tube closure. This could be due to the fact we
did not know how Xenopus embryos with neural tube closure defects might appear. With
more consideration, it is very possible such embryos were present within the treatment
groups as severely deformed embryos that did not continue to develop. In order to
determine if homocysteine or methotrexate treatment affects Xenopus embryos in a
similar manner to that of folate deficiency, the neural tube thickness at four regions was
measured at a later developmental stage in surviving embryos.
Within the methotrexate treated embryos mediolateral sides were the widest. The
increase in ventral measurements did not correspond to increased methotrexate levels.
The width of the dorsal side decreased with increasing concentration of methotrexate,
suggesting that blocking dihydrofolate reductase could lead to failure of neural tube
closure. Similarly, mediolateral measurements were also the largest among homocysteine
treated embryos. However all four measurements fluctuated and were not correlated with
homocysteine concentration. The fact that methotrexate treated embryos had overall
larger neural tube measurements suggests that the embryos used for homocysteine
treatment groups might not have been as the same developmental stage. Also, the
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variability of the homocysteine samples could be due to reduced quality of the embryo
sections.
These results along with that of gross morphological affects and gut coiling
suggest treatment of embryos with homocysteine and methotrexate affect embryos in a
similar manner to that of embryos with folate deficiency. This conclusion is based on the
finding that homocysteine and methotrexate treated embryos showed a delay in
development, altered morphology and at least in methotrexate treated embryos there was
a decrease in the thickness of the dorsal side of the neural tube. Additionally, the effect
on gut coiling corresponds to published findings regarding the treatment of methotrexate.
Altered Folate Metabolism Cause Changes in Specific Gene Expression
Patterns
Paired box gene 3 (Pax-3) is expressed in the dorsal aspect of the neural tube,
from the midbrain level throughout the entire neural axis (Takahashi et al., 1992). Pax-3 
expression occurs during neural plate formation and establishes, in part, the appropriate
spatial information for later arising cells such as neural crest cells (Bang, 1999). In the
absence of this gene, defective differentiation of neuroepithelial cells lead to the failure of
neural tube closure in both midbrain and hindbrain regions (Tang and Finnell, 2003).
Furthermore, Pax-3 expression in nullizygous Folbp1 embryos is decreased compared to
the wild type (Tang and Finnell, 2003). In our studies the reduction in Pax-3 expression
in homocysteine and methotrexate treated embryos suggests that these compounds mimic
folate deficiency and cause a change in Pax-3 expression consistent with the results
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observed in Folbp1 -/- mice. Also, this allowed us to examine to what extent the known
neural tube formation genes such as Pax -3 were affected in Xenopus embryos with
altered folate metabolism. We found that the level of Pax-3 staining in homocysteine
treated embryos was reduced. In a separate in situ hybridization experiment a decreased
level of expression was detected in methotrexate treated embryos (results not shown).
However, in the study shown (Figure 10 and Figure 11), methotrexate did not reduce
Pax-3 expression, and in fact there was a broader pattern of staining. This is likely due to
these embryos being at a later developmental stage. The earliest expression of Pax-3 is
detected as two patches situated at lateral ends of the embryo in the site of neural plate at
stage 11 (Bang et al., 1999). For this reason, we chose to examine Pax-3 expression at
stage 12. Because of the difficulty of growing embryos at exactly the same rate, the
methotrexate treated embryos were collected at a late gastrula stage. Unfortunately, there
were no untreated embryos at this later stage to compare to the methotrexate treated
embryos. It will be necessary to repeat the in situ hybridization studies for Pax-3 and
ensure that treated embryos are developmentally matched to the untreated embryos.
Dkk-1 
 Dkk-1 is expressed in the head organizer and encodes a family of secreted Wnt
inhibitors that antagonize Wnt signaling (Moon et al., 1993). Dkk-1 antibody injection
into Xenopus zygotes results in microcephaly. Dkk-1 is speculated to be required for head
formation (Glinka et al., 1998). Additionally, studies completed in this laboratory and at
the National Institute of Environmental Health Sciences have shown that Dkk-1 
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expression is down regulated in folate deficient cultured human fibroblast cells (Katula et
al., Submitted).
The earliest expression of Dkk-1 is seen in the early gastrula when it is expressed
in the Spemann organizer (Glinka et al., 1998). At stage 10, Dkk-1 expression is detected
in the deep cells within the Spemann organizer. At a later gastrula stage, Dkk-1 is
expressed in three domains. The most anterior expression seen is in cells that give rise to
the liver. The strongest expression is visualized in prospective prechordal plate in a wing
shaped pattern in the middle of the endomesoderm. The third domain consists of two
longitudinal strips. At a later neural stage, Dkk-1 expression is seen in the prechordal
plate adjacent to the prospective forebrain, eyes and somites (Glinka et al., 1998).
Generally, the expression level of Dkk-1 is quite low. In this study, Dkk-1 
expression was detected only in the longitudinal strips. This is likely due to the embryos
being at an earlier stage than the published examples (Table 1). Methotrexate treated
embryos showed a diminished level of expression compared to that of untreated embryos.
Homocysteine treated embryos had the same expression pattern in comparison to
methotrexate with lighter staining, corresponding to reduced expression levels. It is
possible that the smaller eyes evident in some of the embryos treated with high
concentrations of homocysteine and methotrexate could be due to reduced levels of Dkk-
1 expression in prechordal plate during late neural stage.
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Xbra
Xbra is an early mesodermal transcription factor that controls the early Hox gene
expression in animal-vegetal direction (Smith et al., 1991). We chose to include this gene
in our expression studies as it can be a useful control for the in situ hybridization
protocol. We did not expect the expression pattern to change in treated embryos as Xbra
is not involved in neuroectoderm. However, there is no published data regarding
modifications in Xbra expression due to folate deficiency. For this reason, Xbra served
not only as a good control but also a gene of experimental interest.
During gastrulation, Xbra expression is observed in mesodermal cells around the
blastapore as a ring (Table 1). In this study, untreated and homocysteine treated embryos
showed the same expression level and pattern. When these embryos were compared to
methotrexate treated embryos, Xbra expression was reduced in the methotrexate treated
embryos, especially in the cleared embryos. Also, the expression pattern was altered. This
observed pattern is more typical of a later gastrula stage (Smith et al., 1991). The smaller
blastopore and the staining of the notochord in methotrexate treated embryos supports
this conclusion. Thus, it is likely that the decreased staining in methotrexate treated
embryos is a consequence of being at a later developmental stage.
Xtwist
Xtwist is a transcription factor expressed in the neural crest cells (Hopwood et al.,
1989). Staining was observed in the notochord, neural tube, cranial neural crest and
somites. No obvious differences were observed between the untreated and homocysteine
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treated embryos in this study. However, on close examination there appeared to be
greater staining of the somites in the homocysteine treated embryos compared to the
untreated. Again, this could be due to a slight change in the developmental stage.
Methotrexate treated embryos showed a similar expression level and pattern to that of the
homocysteine treated embryos. These results suggest not all transcription factors
expressed in the neural crest cells are affected by folate deficiency.
Wnt-5A
Wnt-5A is a member of the Wnt gene family that encodes for secreted signaling
proteins. Wnt-5A signaling is involved in axis induction through modification in the
morphogenetic movement of tissues (Moon et al., 1993). Also, it has been found that
Wnt-5A expression is up regulated in folate deficient cultured human fibroblast cells
(Katula, submitted). At stage 20 (neurula) normal Wnt-5A expression is prominent in the
anterior and the posterior ectoderm of the embryo (Moon et al., 1993). The in situ
hybridization performed with riboprobe Wnt-5A using our initial protocol resulted in the
neural tube being stained in all treated (homocysteine and methotrexate) and untreated
embryos. These results were considered inconclusive as we were unable to determine if
the staining patterns seen was specific or unspecific staining due to leaving embryo in
alkaline phosphatase substrate, NBT/BCIP, for a long period of time.
During this study many difficulties arose. Having a sufficient number of healthy
embryos was most critical to the success of these studies. Not only a large number of
healthy embryos were required, but embryos derived from the same female were
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necessary. On numerous occasions, Xenopus females produced only a few eggs.
Therefore, we had to collect eggs from more than one female and more than one batch of
eggs from each female. Many of these batches of eggs were not as healthy and did not
generate viable embryos. This could very well be one of the reasons that some treatments
did not produce uniform effects. Incidentally, this is a better representation of the human
population where severity of the effects of folate deficiency is different among babies.
We also had numerous problems performing the in situ hybridization reactions.
One of which, embryos were not showing specific staining. This problem was solved
after following Mr. Daniel D. Brown’s (graduate student at UNC - Chapel Hill) protocol.
In the process of following the initial protocol many of the collected embryos were used
up. As a result we did not have enough treated embryos at the same developmental stage
to perform in situ hybridization with the riboprobe Wnt-5A. Also, the expression level of
Dkk-1 was quite low compared to the expression of genes such as Xbra. To achieve the
desired level of staining for Dkk-1, the embryos were left in staining compounds for long
periods of time. This increased background staining, making it more difficult to analyze
the pattern and level of staining.
We found that homocysteine and methotrexate caused a delay in development.
Such a delay was also observed in Folbp1 nullizygous embryos. It is known that gene
expression levels and patterns change with the developmental stage. To be certain that
these genes are, indeed being affected, it will be important to perform in situ
hybridization reactions at different times around the developmental period when the gene
is normally expressed. If the change in expression pattern and level seen was due to
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homocysteine and methotrexate treatment, the observed difference (increased or
decreased) would be consistent throughout the entire time period. This would enable us to
rule out the possibility that the expression patterns that were observed were due to the
developmental stages. Also, a time course should be done to see to what extend the rate
of development is affected in treated embryos and if at all, how long it takes for the
underdeveloped embryos to exhibit normal development. Moreover, the in situ
hybridized embryos should be sectioned to examine the level of expression at the cellular
level and the amount of specific RNA transcript present in the embryos evaluated by
quantitative RT-PCR. Finally, head structures of the embryos should be analyzed more
closely for the presence of orofacial deformities.
In summary, we attempted to mimic folate deficiency in Xenopus laevis embryos
by treatment with homocysteine and methotrexate and to analyze changes in gene
expression. We found that homocysteine and methotrexate affects Xenopus embryo
development in a manner similar to folate deficiency. Furthermore, our data indicate that
homocysteine and methotrexate alter the expression of specific genes. These results
suggest that the Xenopus laevis model system could possibly be ideal for investigating
the link between folate deficiency and the molecular basis of developmental defects.
They also suggest that folate deficiency affects development through changes in
expression patterns of specific genes, specifically genes involved in or regulated by Wnt
signaling. These results must be validated with additional studies.
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